The findings show that targeting VCP could represent a new therapeutic avenue for HCC by addressing both tumor metabolism and immune dysfunction, offering a synergistic strategy that could improve the efficacy of existing immunotherapies and provide broader applications in cancer treatment. The gene discussed is VCP; the disease is neoplasm.